5214

2013-2014 Regular Sessions

IN ASSEMBLY

February 21, 2013

Introduced by M. of A. TITONE -- Multi-Sponsored by -- M. of A. BARRON -- read once and referred to the Committee on Insurance

AN ACT to amend the insurance law, in relation to the regulation of step therapy and first fail policies

THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-BLY, DO ENACT AS FOLLOWS:

Section 1. The insurance law is amended by adding a new article 33 to read as follows:

> ARTICLE 33 REGULATION OF STEP THERAPY AND FIRST FAIL POLICIES

6 SECTION 3301. DEFINITIONS.

1 2

3

4

5

7 8 3302. PRESCRIPTION DRUG RESTRICTION OVERRIDES.

S 3301. DEFINITIONS. AS USED IN THIS ARTICLE:

9 (A) "INSURER" SHALL MEAN ANY PERSON OR ENTITY WHO OFFERS A POLICY OF ACCIDENT AND/OR HEALTH INSURANCE PURSUANT TO SECTION THREE THOUSAND TWO 10 HUNDRED SIXTEEN, THREE THOUSAND TWO HUNDRED TWENTY-ONE, OR FOUR THOUSAND 11 THREE HUNDRED THREE OF THIS CHAPTER OR ARTICLE FORTY-FOUR OF THE 12 PUBLIC HEALTH LAW, INCLUDING MANAGED CARE PROVIDERS AS DEFINED IN SECTION THREE 13 14 HUNDRED SIXTY-FOUR-J OF THE SOCIAL SERVICES LAW;

15 "PHARMACY BENEFIT MANAGEMENT" OR "PBM" SHALL MEAN THE SERVICE (B) PROVIDED TO AN INSURER, DIRECTLY OR THROUGH ANOTHER ENTITY; 16 INCLUDING THE 17 PROCUREMENT OF PRESCRIPTION DRUGS TO BE DISPENSED TO COVERED PERSONS, OR THE ADMINISTRATION OR MANAGEMENT OF PRESCRIPTION DRUG BENE-18 19 FITS INCLUDING, BUT NOT LIMITED TO, ANY OF THE FOLLOWING: 20

(1) A MAIL ORDER PHARMACY;

(2) CLAIMS PROCESSING, RETAIL NETWORK MANAGEMENT AND PAYMENT OF CLAIMS 21 TO PHARMACIES FOR DISPENSING PRESCRIPTION DRUGS; 22

23 (3) CLINICAL OR OTHER FORMULARY, OR PREFERRED DRUG LIST DEVELOPMENT OR 24 MANAGEMENT;

EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [] is old law to be omitted.

LBD05355-01-3

(4) NEGOTIATION OR ADMINISTRATION OF REBATES, DISCOUNTS, PAYMENT 1 2 DIFFERENTIALS OR OTHER INCENTIVES FOR THE INCLUSION OF PARTICULAR 3 PRESCRIPTION DRUGS IN A PARTICULAR CATEGORY OR TO PROMOTE THE PURCHASE 4 OF PARTICULAR PRESCRIPTION DRUGS; 5 (5) PATIENT COMPLIANCE, THERAPEUTIC INTERVENTION AND GENERIC SUBSTI-6 TUTION PROGRAMS; AND 7 (6) DISEASE MANAGEMENT. 8 S 3302. PRESCRIPTION DRUG RESTRICTION OVERRIDES. (A) WHEN MEDICATIONS 9 FOR THE TREATMENT OF ANY MEDICAL CONDITION ARE RESTRICTED FOR USE BY AN 10 INSURER OR PBM BY A STEP THERAPY OR FAIL FIRST PROTOCOL, A PRESCRIBER SHALL HAVE ACCESS TO A CLEAR AND CONVENIENT PROCESS TO OVERRIDE SUCH 11 12 RESTRICTIONS FROM THE INSURER AND MAY EXPEDITIOUSLY OVERRIDE SUCH 13 **RESTRICTION IF:** 14 (1) SUCH PRESCRIBER, IN HIS OR HER PROFESSIONAL JUDGMENT, BELIEVES 15 THAT THE PREFERRED TREATMENT BY THE INSURER OR THE PBM HAS BEEN INEFFEC-16 TIVE IN THE TREATMENT OF THE COVERED PERSON'S DISEASE OR MEDICAL CONDI-17 TION; OR (2) BASED ON SOUND CLINICAL EVIDENCE AND MEDICAL AND SCIENTIFIC 18 19 EVIDENCE: (A) SUCH PRESCRIBER, IN HIS OR HER PROFESSIONAL JUDGMENT, BELIEVES 20 21 THE PREFERRED TREATMENT IS EXPECTED TO BE INEFFECTIVE BASED ON THE THAT 22 KNOWN RELEVANT PHYSICAL OR MENTAL CHARACTERISTICS OF THE COVERED PERSON AND KNOWN CHARACTERISTICS OF THE DRUG REGIMEN, AND IS LIKELY TO BE INEF-23 FECTIVE OR ADVERSELY AFFECT THE DRUG'S EFFECTIVENESS OR PATIENT COMPLI-24 25 ANCE; OR 26 (B) SUCH PRESCRIBER, IN HIS OR HER PROFESSIONAL JUDGMENT, BELIEVES THAT THE PREFERRED TREATMENT HAS CAUSED OR IS LIKELY TO CAUSE AN ADVERSE 27 28 REACTION OR OTHER HARM TO THE COVERED PERSON. 29 (B) THE DURATION OF ANY STEP THERAPY OR FAIL FIRST PROTOCOL SHALL NOT BE LONGER THAN EITHER (1) THE PERIOD DEEMED NECESSARY BY THE PRESCRIBING 30 PHYSICIAN OR HEALTH CARE PROFESSIONAL TO DETERMINE THE TREATMENT'S CLIN-31 32 ICAL EFFECTIVENESS, OR (2) A PERIOD OF THIRTY DAYS. 33 (C) FOR MEDICATIONS WITH NO GENERIC EQUIVALENT AND FOR WHICH THE PRES-34 CRIBER IN HIS OR HER CLINICAL JUDGMENT BELIEVES THAT NO APPROPRIATE THERAPEUTIC ALTERNATIVE IS AVAILABLE, AN INSURER OR PBM SHALL PROVIDE 35 ACCESS TO UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) LABELED MEDI-36 CATIONS WITHOUT RESTRICTION TO TREAT SUCH MEDICAL CONDITIONS FOR WHICH 37 38 AN FDA LABELED MEDICATION IS AVAILABLE. 39 (D) NOTHING IN THIS SECTION SHALL REQUIRE COVERAGE FOR AN ADDITIONAL 40 CONDITION NOT ALREADY COVERED BY THE POLICY OR CONTRACT, OR WHICH IS NOT 41 OTHERWISE COVERED BY LAW. S 2. This act shall take effect on the one hundred twentieth day after 42 43 it shall have become a law.